Reviva Pharmaceuticals Holdings, Inc.

What they do

Reviva discovers and develops new chemical entities for central nervous system, inflammatory and cardiometabolic diseases using a chemical genomics driven platform and proprietary chemistry. Its pipeline has two in-house discovered candidates: brilaroxazine (RP5063), in clinical development for schizophrenia, bipolar disorder, major depressive disorder, ADHD, BPSD and Parkinson's disease psychosis, and preclinical for PAH, IPF and psoriasis; and RP1208. Its primary focus is completing clinical development of brilaroxazine for acute and maintenance schizophrenia. It has never generated product revenues.

Revenue drivers

• Brilaroxazine (RP5063) — Lead and only advanced product candidate, under clinical development for schizophrenia and other neuropsychiatric indications; intended for an NDA submission for schizophrenia. No product revenue has been generated.
• RP1208 — Second in-house discovered new chemical entity in the pipeline; no revenue contribution and no commercial-stage activity described in the excerpts.
• Respiratory indications for brilaroxazine — Brilaroxazine holds FDA Orphan Drug Designation for PAH (November 2016) and IPF (April 2018) and is described as ready for clinical development; no revenue to date.
• Partnership and financing activity — Company states it is pursuing partnership opportunities for pipeline development and has funded operations through equity issuances including a May 2025 at-market issuance sales agreement; these are funding sources, not product revenue.

Recent performance

For the three months ended June 30, 2026, Reviva reported a net loss of approximately $2.4 million, or $0.19 per share, compared with a net loss of approximately $6.1 million, or $2.40 per share, for the three months ended June 30, 2025. Cash and cash equivalents were approximately $19.9 million as of June 30, 2026, up from approximately $14.4 million as of December 31, 2025. Total assets were $21.1 million, total liabilities $5.9 million and shareholder equity $15.2 million at June 30, 2026. Annual net loss narrowed from $29.9 million in 2024 to $19.9 million in 2025, with operating cash use of $24.6 million in 2025. The company has never generated product revenues.

Strategy

The company's stated priority is completing clinical development of brilaroxazine for acute and maintenance schizophrenia. It filed a U.S. composition of matter patent application seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046, and intends to use this new form in a bridging bioequivalence study, the RECOVER-2 Phase 3 trial and a future NDA submission. It expects FDA feedback on the new formulation in Q4 2026, plans to initiate a bioequivalence study in Q4 2026, and expects RECOVER-2 patient enrollment to initiate in 1H 2027 subject to receipt of additional financing. It is also pursuing partnership opportunities for pipeline development.

Risks

• No product revenue and going concern doubt — The company states it has never generated product revenues and that recurring losses from operations have raised substantial doubt regarding its ability to continue as a going concern.
• Need for substantial additional capital — The company states it will require substantial additional capital and that failure to raise capital when needed or on acceptable terms could force it to delay, reduce or eliminate development programs, including RECOVER-2 and the brilaroxazine NDA.
• Dependence on brilaroxazine — The company states it is heavily dependent on brilaroxazine, its only advanced product candidate, which is still under clinical development, and that failure to obtain regulatory approval or commercialize it would harm the business.
• Listing and liquidity — The common stock was suspended from Nasdaq and began quotation on the OTCQB Venture Market on May 14, 2026, with Nasdaq filing a Form 25 on July 10, 2026 to strike the stock from listing and/or withdraw registration.

Outlook

Management expects FDA feedback in Q4 2026 on use of the new brilaroxazine formulation in the RECOVER-2 trial and the planned NDA. It plans to initiate a bioequivalence study in Q4 2026 and to begin RECOVER-2 patient enrollment in 1H 2027, subject to receipt of additional financing. Additional publications on brilaroxazine for schizophrenia are expected in Q4 2026, and the company says it is pursuing partnership opportunities for its pipeline.